Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553648 | 0.84 | HSD11B1 (0.58) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3547254 | 0.82 | HSD11B1 (0.70) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3555295 | 0.80 | HSD11B1 (0.73) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13036473 | 0.78 | HSD11B1 (0.64) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL11959875 | 0.75 | HSD11B1 (1.00) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13036462 | 0.75 | HSD11B1 (1.00) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL11959849 | 0.75 | HSD11B1 (1.00) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13036465 | 0.72 | CYP3A4 (0.68) | HSD11B1CYP3A4CYP2C19KMT2A | |
| SCHEMBL11959680 | 0.72 | CYP3A4 (0.68) | HSD11B1CYP3A4CYP2C19KMT2A | |
| SCHEMBL14208998 | 0.72 | HSD11B1 (0.69) | HSD11B1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753421-B1 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN INC (US) | 2012-08-01 | — | — | EP | claimed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | claimed |
| US-20090075975-A1 | ARYLSULFONAMIDES AND USES RELATED THERETO | AMGEN INC. | 2009-03-19 | — | — | US | claimed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | claimed |
| EP-1753421-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | Amgen Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2005-12-29 | — | — | US | claimed |
| WO-2005118538-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| EP-3194615-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016034742-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-03-10 | — | — | WO | disclosed |
| EP-1753421-B1 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1753421-B1 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-7834047-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090075975-A1 | ARYLSULFONAMIDES AND USES RELATED THERETO | AMGEN INC. | 2009-03-19 | — | — | US | disclosed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495012-B2 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1753421-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | Amgen Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2005-12-29 | — | — | US | disclosed |
| WO-2005118538-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075975-A1 | ARYLSULFONAMIDES AND USES RELATED THERETO | ARSA, STS, SULT2A1 | HSD11B1 162/4885PSEN1 3323/4885PSEN2 3388/4885 |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | ARSA, STS, SULT2A1 | HSD11B1 162/4885PSEN1 3323/4885PSEN2 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.